The Trend of ripk1/ripk3 and mlkl Mediated Necroptosis Pathway in Patients with Different Stages of Prostate Cancer as Promising Progression Biomarkers

Heidaryan, Farnaz; Bamehr, Hadi; Babaabasi, Babak; Emamvirdizadeh, Alireza; Mohammadzadeh, Nima; Khalili, Ahmad

doi:10.7754/clin.lab.2019.190439

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sorafenib is a 2nd generation tyrosine kinase inhibitor (TKI) that targets Raf kinases, including Raf-1 and b-Raf, VEGFR-2 and -3, PDGFR-β, Flt-3, and c-KIT ( Kharaziha et al, 2015 ). In the Atg5-deficient prostate cancer cell line DU-145, sorafenib could mediate necroptosis by inducing the RIPK1/RIPK3/MLKL pathway, and this process can be blocked by the RIPK1 inhibitor Nec-1 ( Heidaryan et al, 2020 ). Even in androgen-dependent prostate cancer, necroptosis can be induced in LNCaP cells through activation of RIPK1 by Ophiopogonin D′ (OPD′); the use of either Nec-1 or necrosulfonamide, a kind of MLKL inhibitor, can inhibit necroptosis induced by OPD′ ( Wang J. et al, 2017 ).…”

Section: Rcds In Urinary Malignanciesmentioning

confidence: 99%

Regulated Cell Death in Urinary Malignancies

Nie

Chen

Gao

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Urinary malignancies refer to a series of malignant tumors that occur in the urinary system and mainly include kidney, bladder, and prostate cancers. Although local or systemic radiotherapy and chemotherapy, immunotherapy, castration therapy and other methods have been applied to treat these diseases, their high recurrence and metastasis rate remain problems for patients. With in-depth research on the pathogenesis of urinary malignant tumors, this work suggests that regulatory cell death (RCD) plays an important role in their occurrence and development. These RCD pathways are stimulated by various internal and external environmental factors and can induce cell death or permit cell survival under the control of various signal molecules, thereby affecting tumor progression or therapeutic efficacy. Among the previously reported RCD methods, necroptosis, pyroptosis, ferroptosis, and neutrophil extracellular traps (NETs) have attracted research attention. These modes transmit death signals through signal molecules, such as cysteine-aspartic proteases (caspase) family and tumor necrosis factor-α (TNF-α) that have a wide and profound influence on tumor proliferation or death and even change the sensitivity of tumor cells to therapy. This review discussed the effects of necroptosis, pyroptosis, ferroptosis, and NETs on kidney, bladder and prostate cancer and summarized the latest research and achievements in these fields. Future directions and possibility of improving the denouement of urinary system tumors treatment by targeting RCD therapy were also explored.

show abstract

Section: Rcds In Urinary Malignanciesmentioning

confidence: 99%

Regulated Cell Death in Urinary Malignancies

Nie

Chen

Gao

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…By appending alkyne substituents to GSK′772, another series of benzoxazepinones that occupy both the allosteric site and the ATP pocket was developed. 127 Of the compounds prepared, the cyclopropyl analogue ZB-R-55 (16, Figure 6) was the most potent in cellular assays (IC 50 = 0.34 nM against U937 cells stimulated with TNF, a SMAC mimetic, and zVAD.fmk) and enzymatic assays (IC 50 = 5.7 nM by ADP-Glo and 16 nM by 33 P-radiolabeled assay). 127 ZB-R-55 retained the exquisite kinase selectivity of the benzoxazepinone class, showing <30% inhibition of kinase activity against the Reaction Biology Corp and Eurofins panels when tested at 1 μM.…”

Section: Development Of Necroptosis Inhibitorsmentioning

confidence: 99%

From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors

et al. 2023

View full text Add to dashboard Cite

Necroptosis is a regulated caspase-independent form of necrotic cell death that results in an inflammatory phenotype. This process contributes profoundly to the pathophysiology of numerous neurodegenerative, cardiovascular, infectious, malignant, and inflammatory diseases. Receptor-interacting protein kinase 1 (RIPK1), RIPK3, and the mixed lineage kinase domain-like protein (MLKL) pseudokinase have been identified as the key components of necroptosis signaling and are the most promising targets for therapeutic intervention. Here, we review recent developments in the field of small-molecule inhibitors of necroptosis signaling, provide guidelines for their use as chemical probes to study necroptosis, and assess the therapeutic challenges and opportunities of such inhibitors in the treatment of a range of clinical indications.

show abstract

“…Recent studies report a new PCD mechanism, PANoptosis, which is based on the formation of the PANoptosome, a molecular complex composed of molecules governing apoptosis, necroptosis and PYR [ 12 , 13 ]. The diverse PCD mechanisms are classified on the basis of gene expression, biochemical and cellular morphological properties as well as different effector molecules representing potential selective biomarkers and targets useful for fighting cancer [ 14 , 15 ]. In this regard, the discovery of drugs that stimulate apoptosis has attracted attention and research investment [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

The Therapeutic Potential of Pyroptosis in Melanoma

Zaffaroni

Beretta

2023

IJMS

View full text Add to dashboard Cite

Pyroptosis is a programmed cell death characterized by the rupture of the plasma membranes and release of cellular content leading to inflammatory reaction. Four cellular mechanisms inducing pyroptosis have been reported thus far, including the (i) caspase 1-mediated canonical, (ii) caspase 4/5/11-mediated non-canonical, (iii) caspase 3/8-mediated and (iv) caspase-independent pathways. Although discovered as a defense mechanism protecting cells from infections of intracellular pathogens, pyroptosis plays roles in tumor initiation, progression and metastasis of tumors, as well as in treatment response to antitumor drugs and, consequently, patient outcome. Pyroptosis induction following antitumor therapies has been reported in several tumor types, including lung, colorectal and gastric cancer, hepatocellular carcinoma and melanoma. This review provides an overview of the cellular pathways of pyroptosis and discusses the therapeutic potential of pyroptosis induction in cancer, particularly in melanoma.

show abstract

The Trend of ripk1/ripk3 and mlkl Mediated Necroptosis Pathway in Patients with Different Stages of Prostate Cancer as Promising Progression Biomarkers

Cited by 8 publications

References 0 publications

Regulated Cell Death in Urinary Malignancies

Regulated Cell Death in Urinary Malignancies

From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors

The Therapeutic Potential of Pyroptosis in Melanoma

Contact Info

Product

Resources

About